Acute myeloid leukemia electrocardiogram

Jump to: navigation, search

Acute myeloid leukemia Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Acute myeloid leukemia from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardigram

Chest X Ray

Echocardiograph and Ultrasound

CT

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Acute myeloid leukemia electrocardiogram On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Acute myeloid leukemia electrocardiogram

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Acute myeloid leukemia electrocardiogram

CDC on Acute myeloid leukemia electrocardiogram

Acute myeloid leukemia electrocardiogram in the news

Blogs on Acute myeloid leukemia electrocardiogram

Directions to Hospitals Treating Acute myeloid leukemia

Risk calculators and risk factors for Acute myeloid leukemia electrocardiogram

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Shyam Patel [2]; Grammar Reviewer: Natalie Harpenau, B.S.[3]

Overview

Electrocardiogram is useful for assessment of QT interval prior to starting treatment with ivosidenib and arsenic trioxide. It is also useful for assessing arrhythmias induced by anthracycline chemotherapy.

Electrocardiogram

The indications for electrocardiogram in acute myeloid leukemia include the following:

  • Assessment of QT interval: Arsenic trioxide and ivosidenib are know to cause QT prolongation. An electrocardiogram should be assessed at baseline prior to the start of these therapies. The risk of QT prolongation with ivosidenib is 8%, per the phase 1 dose-escalation and dose-expansion study for this agent.[1] Electrocardiograms should be obtained every 3 months while on therapy. If the QT interval is greater than 500 milliseconds, the therapy should be discontinued.
  • Assessment of arrhythmias: Anthracyclines such as idarubicin or doxorubicin can result in arrhythmias soon after infusion. Arrhythmias are a rare but known complication of anthracycline. Electrocardiogram is diagnostic of the specific type of arrhythmia.[2]


References

  1. Stein EM, DiNardo CD, Pollyea DA, Fathi AT, Roboz GJ, Altman JK; et al. (2017). "Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia". Blood. 130 (6): 722–731. doi:10.1182/blood-2017-04-779405. PMC 5572791. PMID 28588020.
  2. Hefti E, Blanco JG (2016). "Anthracycline-Related Cardiotoxicity in Patients with Acute Myeloid Leukemia and Down Syndrome: A Literature Review". Cardiovasc Toxicol. 16 (1): 5–13. doi:10.1007/s12012-015-9307-1. PMC 4514565. PMID 25616318.

Linked-in.jpg